Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room: Transparency notification


[13/01/2020 | 20:10]

** Transparency notification BlackRock, Inc.

=C2=B7 Notification referring to situation on 7 January 2020
=C2=B7 Threshold crossed: 5%
=C2=B7 Latest holding: 5.18%=C2=A0

Brussels (Belgium), 13 January 2020 =E2=80=93 20:00 (CET) =E2=80=93 regulat=
ed information

1.=C2=A0 Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large =
shareholdings, UCB SA/NV announces that it has received a transparency noti=
fication from BlackRock, Inc. (having its registered office at 55 East 52nd=
Street, New York, NY, 10055, U.S.A.), dated 8 January 2020.

BlackRock, Inc., has notified that, following an acquisition of UCB shares =
with voting rights by its affiliates, its holding of UCB shares with voting=
rights has increased and has crossed the 5% threshold on 7 January 2020.=

On 7 January 2020, BlackRock, Inc. (taking into account the holding of its =
affiliates) Inc. owned=C2=A09 927 826 UCB shares with voting rights (versus=
9 647 211 shares in its previous notification), representing 5.10% of the =
total number of shares issued by the company (194 505 658) (versus 4.96% in=
its previous notification), as well as 153 082 equivalent financial instru=
ments (versus 150 268 in its previous notification) representing 0.08% of t=
he total number of shares issued by the company (same % as in its previous =

2.=C2=A0=C2=A0 =C2=A0Content of the notification

=C2=B7 Reason for the notification: Acquisition or disposal of voting secur=
ities or voting rights.=C2=A0
=C2=B7 Notification by: A parent undertaking or a controlling person.
=C2=B7 Persons subject to the notification requirement:=C2=A0


=C2=B7 Date on which the threshold is crossed: 7 January 2020.
=C2=B7 Threshold crossed (in %): 5%
=C2=B7 Denominator: 194 505 658.
=C2=B7 Notified details:



=C2=B7 Chain of controlled undertakings through which the holding is effect=
ively held:

Please see the full chain of control in the =E2=80=98Chain of Control=E2=80=
=99 tab.

=C2=B7 Additional information:=C2=A0

The disclosure obligation arose due to voting rights attached to shares for=
BlackRock, Inc. going above 5%.=C2=A0

3.=C2=A0 Further information=C2=A0

This press release and the detailed transparency notification are available=
on UCB SA/NV=E2=80=99s website via the following link (https://www.ucb.com=
/investors/UCB-shareholders) .

An updated overview of the UCB SA/NV large shareholdings will be available =
on UCB SA/NV=E2=80=99s website via the following link (https://www.ucb.com/=
investors/UCB-shareholders) .

Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With 7 500 people in approxima=
tely 40 countries, the company generated revenue of =E2=82=AC 4.6 billion i=
n 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
Capture 1 Transparency Notification Jan 13 2020 (https://mb.cision.com/Publ=
ic/18595/3007892/ac73b921d3780ee9_org.jpg) Image
Capture 2 Transparency Notification Jan 13 2020 (https://mb.cision.com/Publ=
ic/18595/3007892/a821fa78f210c54d_org.jpg) Image
Capture 3 Transparency Notification Jan 13 2020 (https://mb.cision.com/Publ=
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x33309x1x6868579x24000=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=